Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: Correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b

Neurological Research

Volumn 34, Issue 6, 2012, Pages 611-618

  Minagar, Alireza ^a   Ma, Wanlong ^b   Zhang, Xi ^b   Wang, Xiuqiang ^b   Zhang, Ke ^b   Steven Alexander, J ^c   Gonzalez Toledo, Eduardo ^a   Albitar, Maher ^b  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Chymotrypsin like activity; Multiple sclerosis; Proteasome; Response; Survival; Ubiquitin

Indexed keywords

GADOLINIUM PENTETATE; PROTEASOME; RECOMBINANT BETA INTERFERON; RECOMBINANT BETA INTERFERON 1B; UBIQUITIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMAGING; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; YOUNG ADULT;

EID: 84864106711     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000055     Document Type: Article

References (22)

1. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest. 2001;81:263-81.
2. Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol. 1999;98:49-56.
3. Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol. 2001;14:259-69.
4. Miller SD, McRae BL, Vanderlugt CL, Nikcevich KM, Pope JG, Pope L, et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol Rev. 1995;144:225-44.
5. Tuohy VK, Yu M, Yin L, Kawczak JA, Johnson JM, Mathisen PM, et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev. 1998;164:93-100.
6. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol. 1995;2:503-8.
7. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801-47.
8. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science. 1996;274:1652-9.
9. Zheng J, Bizzozero OA. Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis. J Neurochem. 2011;117: 143-53.
10. Appel S, Brossart P. Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. Endocr Metab Immune Disord Drug Targets. 2007;7:93-7.
11. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol. 2006;3:255-61.
12. Reinstein E. Immunologic aspects of protein degradation by the ubiquitin-proteasome system. Isr Med Assoc J. 2004;6:420-4.
13. Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke. 2004;35:1506-18.
14. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO Rep. 2009;10:706-13.
15. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem. 2009;78: 769-96.
16. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med. 2006;145:676-84.
17. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005;12:1178-90.
18. Drews O, Wildgruber R, Zong C, Sukop U, Nissum M, Weber G, et al. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol Cell Proteomics. 2007;6:2021-31.
19. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, et al. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008;112:1306-12.
20. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, et al. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009;15:3820-6.
21. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, et al. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011;35:526-33.
22. Zoeger A, Blau M, Egerer K, Feist E, Dahlmann B. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem. 2006;52:2079-86.